Sixty Degrees Pharmaceuticals

Executive Summary

Sixty Degrees Pharmaceuticals (60P) is a privately held specialty pharmaceutical company headquartered in Washington, D.C., focused on developing and commercializing therapies for infectious diseases, including COVID-19, malaria, and dengue. Founded in 2011, the company leverages small molecule drug discovery to address unmet medical needs in global health. While currently in the preclinical and early clinical stages, 60P aims to advance its pipeline through internal research and potential partnerships. The company's niche focus on neglected tropical diseases and pandemic threats positions it to capitalize on ongoing public health priorities, though it faces significant development risks and lacks near-term revenue streams. Given its private status and early-stage programs, the company requires external financing and successful clinical outcomes to achieve value inflection.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for COVID-19 oral antiviral candidate20% success
• Q2 2027Initiation of Phase 1 trial for dengue antiviral35% success